Stock Ticker

  • Loading stock data...

Merck & Co’s (NYSE:MRK) Lung Cancer Treatment Dominance With Keytruda Challenged By The Likes Of Regeneron

Over the years, Merck & Co’s (NYSE:MRK) blockbuster cancer treatment, Keytruda, has been the standard first-line treatment alternative for most burdensome lung cancers, but this dominance is about to change. Recently at a cancer research conference, several companies challenged the treatment with their won cancer drugs. Merck’s blockbuster cancer treatment could face competition from new […]

Sign Up To Get Our Latest Stocks Alerts